Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

Elmind Capital LP acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,255,700,000. Supernus Pharmaceuticals makes up about 0.8% of Elmind Capital LP’s investment portfolio, making the stock its 25th biggest position. Elmind Capital LP owned 0.12% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 660 shares during the last quarter. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $49,000. EverSource Wealth Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $51,000. Hantz Financial Services Inc. grew its holdings in shares of Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $55,000.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $45.36 on Wednesday. The firm’s 50-day moving average is $46.80 and its 200-day moving average is $48.78. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -23.62, a PEG ratio of 0.83 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 52-week low of $42.45 and a 52-week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The business had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.40 EPS. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several analyst reports. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.